Cardiff Oncology (FRA:XE7C) Margin of Safety % (DCF Earnings Based) : N/A (As of Dec. 14, 2024)

View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cardiff Oncology's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of Cardiff Oncology's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, Cardiff Oncology's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiff Oncology's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Margin of Safety % (DCF Earnings Based) falls into.

Cardiff Oncology Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiff Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (FRA:XE7C) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

CRDF:USA

Address

11055 Flintkote Avenue, San Diego, CA, USA, 92121

Website

https://www.cardiffoncology.com

Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Cardiff Oncology Headlines

No Headlines